Trials
April 4, 2017
Amy Mcandrew, Will Lawn, Tobias Stevens et al.
20 citations
BACKGROUND: Worldwide, alcohol abuse is a burgeoning problem. Abstinence is key to allow recovery of physical and mental health as well as quality of life, but treatment for alcohol dependence is associated with high relapse rates. Preliminary data have suggested that a combined repeated ketamine and psychological therapy programme may be effective in reducing relapse in severe alcohol use...
April 3, 2017
S. Kose, M. Çetin
Although a number of medications are available for treatment of depressive disorders, one of the major limitations of all present antidepressants is delayed onset of action [1]. In addition, despite recent advances in the pharmacological and non-pharmacological treatment of major depressive disorder, almost one third of patients fail to respond to any treatments [2]. In recent years, one of the...
The FASEB Journal
April 1, 2017
Melodi Ann Bowman, Melissa Vitela, W. Anthony Owens et al.
Twenty percent of adults are diagnosed with major depressive disorder, which is typically treated with selective serotonin reuptake inhibitors. However, this type of medication takes approximately six weeks to produce therapeutic effects. Recently, low doses of ketamine, a noncompetitive N‐methyl‐D‐aspartate (NMDA) receptor antagonist, have been shown to produce rapid and long‐lasting...
Journal of Clinical Psychopharmacology
April 1, 2017
Thomas G. Adams, M. Bloch, Christopher Pittenger
To the Editors: R efractory obsessive-compulsive disorder (OCD) is a common and vexing clinical problem. Agents that modulate glutamate, including theN-methyl-Daspartate antagonist ketamine, have been the focus of recent interest for the treatment of this population, but experience to date has been mixed. Ketamine is a rapid-acting antidepressant that enhances cellular mechanisms associated...
European Psychiatry
April 1, 2017
L.C. Del Sant, E. Magalhães, Ana C. Lucchese et al.
Introduction: The non-competitive N-methyl-d-aspartate glutamate receptor antagonist ketamine has been shown to have rapid antidepressant effects in treatment-resistant depression (TRD). However, only a few studies have investigated which clinical characteristics predict a response to ketamine. Objectives: To assess sociodemographic variables and clinical markers that predict response to...
European Psychiatry
April 1, 2017
M. Cigognini, R. Moreno
Introduction: Several studies have shown that ketamine, an antagonist of NMDA receptors, represents a promising alternative in the treatment of depression. The therapeutic use of ketamine, commonly used at a dose of 0.5 mg/kg, and in a single application IV has been short and requires monitoring in a hospital setting. IM use has been shown to be effective in treating depression and suicide...
The Journal of Clinical Psychiatry
April 2017
Chittaranjan Andrade
Ketamine is an anesthetic drug that is also used for off-label indications such as the mediation of analgesia and sedation in various settings. It is additionally recognized as an agent with antidepressant potential. For depression, it is most commonly administered as a slow intravenous infusion in subanesthetic doses (usually 0.5 mg/kg). As an antidepressant, is strikingly different from...
Journal of Pharmacology and Experimental Therapeutics
April 2017
J M Witkin, S N Mitchell, K A Wafford et al.
The ability of the N-methyl-d-aspartate receptor antagonist ketamine to alleviate symptoms in patients suffering from treatment-resistant depression (TRD) is well documented. In this paper, we directly compare in vivo biologic responses in rodents elicited by a recently discovered metabotropic glutamate (mGlu) 2/3 receptor antagonist...
Brain Structure and Function
April 2017
Anna S. Höflich, Andreas Hahn, Martin Küblböck et al.
Over the last years, a number of studies have been conducted to clarify the neurobiological correlates of ketamine application. However, comprehensive information regarding the influence of ketamine on cortical activity is still lacking. Using resting-state functional MRI and integrating pharmacokinetic information, a double-blind, randomized, placebo-controlled, crossover study was performed...
Therapeutic Advances in Psychopharmacology
April 1, 2017
Álvaro López-díaz, José Luis Fernández-gonzález, José Evaristo Luján-jiménez et al.
27 citations
The rapidly-acting antidepressant properties of ketamine are a trend topic in psychiatry. Despite its robust effects, these are ephemeral and can lead to certain adverse events. For this reason, there is still a general concern around the off-label use of ketamine in clinical practice settings. Nonetheless, for refractory depression, it should be an indication to consider. We report the case of...
European Psychiatry
April 1, 2017
Lucie Bartova, Ana Weidenauer, Markus Dold et al.
IntroductionTreatment resistant depression (TRD) affecting approximately 10–30% of all depressed patients often remains misdiagnosed and undertreated, leading to a higher risk of relapse and suicide. Electroconvulsive therapy (ECT) and sub-anesthetic ketamine have repeatedly shown to be effective in the TRD population. Administering ketamine as an anesthetic component to augment antidepressant...
Translational Psychiatry
March 21, 2017
Drew D. Kiraly, Sarah R. Horn, Nicholas T. van Dam et al.
182 citations
Abstract A subset of patients with depression have elevated levels of inflammatory cytokines, and some studies demonstrate interaction between inflammatory factors and treatment outcome. However, most studies focus on only a narrow subset of factors in a patient sample. In the current study, we analyzed broad immune profiles in blood from patients with treatment-resistant depression (TRD) at...
Pain Medicine
March 10, 2017
Mala C. Mandyam, Neera K. Ahuja
10 citations
Dear Editor, Complex regional pain syndrome (CRPS) describes a disease of localized chronic pain that often occurs after preceding trauma, is out of proportion to its expected course, and includes other symptoms such as hair loss and allodynia [1]. There are no known psychologic or personality factors associated with its development [2]. Therapy is multimodal, and pharmacologic treatments...
International Journal of Psychiatry in Clinical Practice
March 2017
Christoph Kraus, Ulrich Rabl, Thomas Vanicek et al.
Clinical trials demonstrated that ketamine exhibits rapid antidepressant efficacy when administered in subanaesthetic dosages. We reviewed currently available literature investigating efficacy, response rates and safety profile. Twelve studies investigating unipolar, seven on bipolar depression were included after search in medline, scopus and web of science. Randomized, placebo-controlled or...
Efficacy and Mechanism Evaluation
March 1, 2017
Ian M. Anderson, Andrew M. Blamire, Tim Branton et al.
15 citations
Background Electroconvulsive therapy (ECT) is the most effective acute treatment for severe depression, but there are concerns about its adverse cognitive effects. ECT may impair cognition through stimulation of glutamate receptors, and preliminary evidence has suggested that ketamine, a glutamate antagonist, may alleviate these effects. Ketamine has been shown to have a rapid, but temporary,...
INTERNATIONAL JOURNAL OF TOXICOLOGICAL AND PHARMACOLOGICAL RESEARCH
March 1, 2017
Monu Yadav, Milind Parle, Mamta Sachdeva et al.
Psychosis is a complex mental illness, characterised by positive, negative and cognitive symptoms. NMDA receptor antagonists have been established to induce behavioural as well as biochemical changes in rodents similar to psychotic patients. The aim of the present study was to investigate the effective dose and treatment period of ketamine to induce some behavioural changes. The results suggest...
JAMA Psychiatry
March 1, 2017
Gerard Sanacora, Mark A Frye, William M. Mcdonald et al.
577 citations
IMPORTANCE: Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of...
Drugs
March 1, 2017
Marc S. Lener, Bashkim Kadriu, Carlos A. Zarate
Clinical and preclinical studies suggest that dysfunction of the glutamatergic system is implicated in mood disorders such as major depressive disorder and bipolar depression. In clinical studies of individuals with major depressive disorder and bipolar depression, rapid reductions in depressive symptoms have been observed in response to subanesthetic-dose ketamine, an agent whose mechanism of...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
February 28, 2017
N. Kraguljac, Matthew S. Carle, M. Frölich et al.
Retracted
Background Converging evidence from neuroimaging and post-mortem studies suggests that hippocampal subfields are differentially affected in schizophrenia. Recent studies report dentate gyrus dysfunction in chronic schizophrenia, but the underlying mechanisms remain to be elucidated. Here we sought examine if this deficit is already present in first episode psychosis, and if N-methyl-d-aspartate...
Current Neuropharmacology
February 23, 2017
Shigeyuki Chaki
40 citations
BACKGROUND: Ketamine has been reported to exert rapid and sustained antidepressant effects in patients with depression, including patients with treatment-resistant depression. However, ketamine has several drawbacks such as psychotomimetic/dissociative symptoms, abuse potential and neurotoxicity, all of which prevent its routine use in daily clinical practice. METHODS: Therefore, development of...